文献速递母胎医学

在超过8000例无主要结构异常的妊娠中扩展性无创产前筛查与染色体微阵列分析的临床效用比较

Clinical utility of expanded non-invasive prenatal screening compared with chromosomal microarray analysis in over 8000 pregnancies without major structural anomaly.
PubMed 文献 · Ultrasound Obstet Gynecol · 2023-01-01

本回顾性队列研究基于8605例超声正常妊娠的CMA结果,评估扩展性NIPS相对于5-NIPS的理论附加价值并与CMA比较。5-NIPS和全基因组NIPS分别会漏检63.9%和54.1%的临床显著CMA发现,扩展NIPS的附加价值远低于CMA(0.91%)。

要点

  • 8605例超声正常妊娠中CMA检出122例(1.4%)临床显著结果,5-NIPS理论上仅可检出44例(36.1%)。
  • 扩展常见微缺失的NIPS附加价值约0.035%,全基因组NIPS针对大CNV的总体附加价值约0.14%,均远低于CMA的0.91%。
  • 5-NIPS和全基因组NIPS分别会漏检63.9%和54.1%的临床显著CMA发现。

核心结论

  • 5-NIPS甚至全基因组NIPS会分别漏检63.9%和54.1%的临床显著CMA发现。
  • 扩展常见微缺失的NIPS相对于5-NIPS的附加价值约0.035%,全基因组NIPS针对大CNV的总体附加价值约0.14%,均远低于CMA的附加价值(0.91%)。
  • 这些发现应有助于医疗从业者指导夫妇在侵入性产前检测与NIPS之间做出知情决策。

研究设计与样本

  • 本研究为回顾性队列研究,基于2013年1月至2022年2月在Rabin医学中心遗传实验室数据库中登记的所有超声正常(包括软指标和母血清筛查异常)并接受羊膜穿刺的妊娠的CMA结果。
  • 共纳入8605例妊娠,按侵入性检测指征分为亚组。
  • 计算5-NIPS的理论检出率,并比较扩展5-NIPS(常见微缺失:1p36.3-1p36.2、4p16.3-4p16.2、5p15.3-5p15.1、15q11.2-15q13.1和22q11.2)和全基因组NIPS(包括>5 Mb的变异)相对于5-NIPS的附加价值与CMA的附加价值。

主要发现

  • 8605例受检妊娠中,122例(1.4%)显示临床显著CMA结果。
  • 122例中44例(36.1%)理论上可被5-NIPS检出,其中母血清筛查异常642例中检出率为1.56%,软指标318例中为0.63%,高龄(≥35岁)4378例中为0.62%,<35岁3267例中为0.15%。
  • 在总体队列中,除5-NIPS可检出的非整倍体外,扩展常见微缺失NIPS可检出3例(0.03%),全基因组NIPS(排除常见微缺失)可检出9例(0.10%)。
  • 在总体队列和各亚组中,扩展NIPS工具相对于5-NIPS的附加价值均显著低于CMA的附加价值。

关键数值与推荐

  • 5-NIPS可检出44/122(36.1%)临床显著CMA结果。
  • 扩展常见微缺失的NIPS相对于5-NIPS的附加价值约0.035%。
  • 全基因组NIPS针对大CNV的总体附加价值约0.14%。
  • CMA的附加价值为0.91%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the theoretical added value of two types of non-invasive prenatal screening (NIPS) expansions in pregnancies without major structural anomalies over the commonly used NIPS for chromosomes 13, 18, 21, X and Y (5-NIPS) and to compare them with the added value of chromosomal microarray analysis (CMA). METHODS: This was a retrospective cohort study based on CMA results of all pregnancies with normal ultrasound (including pregnancies with soft markers and with abnormal maternal serum screening) that had undergone amniocentesis between January 2013 to February 2022 and were registered in the database of the Rabin Medical Center genetic laboratory. We calculated the theoretical yield of 5-NIPS and compared the added value of expanded 5-NIPS for common microdeletions (1p36.3-1p36.2, 4p16.3-4p16.2, 5p15.3-5p15.1, 15q11.2-15q13.1 and 22q11.2) and genome-wide NIPS (including variants > 5 Mb) with the added value of CMA in the overall cohort and in subgroups according to indication for invasive testing. RESULTS: Among the 8605 examined pregnancies, 122 (1.4%) clinically significant CMA results were demonstrated. Of these, 44 (36.1%) were theoretically detectable on 5-NIPS, with the rates of 1.56% in 642 pregnancies with abnormal maternal serum screening, 0.63% in 318 pregnancies with soft markers, 0.62% in 4378 women with advanced maternal age (≥ 35 years) and 0.15% in 3267 women younger than 35 years. In addition to aneuploidies detectable on 5-NIPS, three (0.03%) cases detectable on 5-NIPS expanded for common microdeletions and nine (0.10%) cases detectable on genome-wide NIPS (excluding common microdeletions) were identified in the overall cohort. The added value of expanded NIPS tools over 5-NIPS was significantly lower compared with that of CMA, for the overall cohort and subgroups. CONCLUSIONS: 5-NIPS and even genome-wide NIPS would miss 63.9% and 54.1% of clinically significant CMA findings, respectively. The added value of 5-NIPS expanded to detect common microdeletions over 5-NIPS is about 0.035%, and the overall added value of genome-wide NIPS aimed at large CNVs is about 0.14%, both much lower compared with the added value of CMA (0.91%). These findings should assist healthcare practitioners in guiding couples towards informed decision-making regarding the choice between prenatal invasive testing and NIPS. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Maya I, Salzer Sheelo L, Brabbing-Goldstein D, et al. Clinical utility of expanded non-invasive prenatal screening compared with chromosomal microarray analysis in over 8000 pregnancies without major structural anomaly. Ultrasound Obstet Gynecol. 2023. PMID: 36776119. doi:10.1002/uog.26177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。